Streetbeat News

Analyst Ratings

SRPT

RBC Capital has maintained its 'Outperform' rating on Sarepta Therapeutics and slightly raised the price target from $181 to $182.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:25 pm

PBF

BMO Capital has downgraded PBF Energy from Outperform to Market Perform and reduced its price target from $42 to $35.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:23 pm

IMAX

Rosenblatt analyst Steve Frankel maintains a Buy rating on Imax (NYSE:IMAX) with a $28 price target.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:23 pm

ZM

Rosenblatt analyst Catharine Trebnick maintains a Buy rating on Zoom Video Communications (NASDAQ:ZM) with a price target of $78.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:19 pm

SAGE

RBC Capital has downgraded Sage Therapeutics from Sector Perform to Underperform and reduced its price target from $10 to $4.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:18 pm

JD

Recent options activity for JD.com shows a bearish sentiment among large investors, with 53% of trades being bearish. The options trades indicate a price range of $22.5 to $60.0. JD.com's stock is currently up 4.04% at $46.4, but RSI indicators suggest it may be overbought.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 3:16 pm

EVGO

Recent options trading activity for EVgo (NASDAQ:EVGO) shows a bearish sentiment among large investors, with 53% of trades being bearish. The price target for EVgo is between $4.0 and $7.0, with the current stock price at $6.88. Analysts have mixed ratings, with price targets ranging from $5 to $7.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 3:16 pm

BANR

MHK

MSGE

SLB

TMP

Benzinga's Stock Whisper Index highlights five stocks gaining interest: Mohawk Industries, Banner Bank, Madison Square Garden Entertainment, Schlumberger, and Tompkins Financial. These stocks are being monitored due to factors like interest rate cuts, upcoming earnings reports, and geopolitical tensions.

Portfolio Pulse from Chris Katje

October 04, 2024 | 3:14 pm

TRVI

EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Trevi Therapeutics (NASDAQ:TRVI) and maintained a price target of $21.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:14 pm

REGN

RBC Capital analyst Brian Abrahams maintains an Outperform rating on Regeneron Pharmaceuticals and raises the price target from $1252 to $1260.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:11 pm